People
Movers &Shakers
British geneticist David Baulcombe, from the University of Cambridge, has been awarded the £500,000 Balzan prize in epigenetics. The citation for the prize reads: ‘For his fundamental contribution to the understanding of epigenetics and its role in cell and tissue development under normal and stressful conditions.’
The UK’s Technology Strategy Board has appointed John Brown as chairman of the Cell Therapy Catapult centre.
SmartKem, a developer of organic semiconductor materials for flexible electronics, has appointed three new team members in Europe. Hugh Williamson becomes ceo; and Muhammad Raza and Keith Lumbard will join as scientists at SmartKem’s dedicated chemistry synthesis labs in Manchester.
Oxford-based Circassia, a specialty biopharmaceutical company focused on allergy, has appointed Brett Haumann as chief medical officer. Haumann joins from GlaxoSmithKline where he was vice president and medicines development leader responsible for the late-stage development of once-daily inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Mucosis, a Dutch clinical-stage biotechnology company developing mucosal vaccines, has appointed Thomas Johnston as ceo. He joined from Novavax, a clinical-stage biopharmaceutical company, and succeeds Govert Schouten who is leaving to found an internet start-up.
Transgene has recruited Nathalie Adda for the position of chief medical officer, responsible for medical and regulatory affairs. As a medical
42 Chemistry&Industry • November 2012
Find C&I online at
www.soci.org/chemistryandindustry
doctor, she specialised in infectious diseases. Adda will also be a member of Transgene’s executive committee.
German-American cancer molecular diagnostics company Epigenomics has appointed Thomas Taapken, formerly chief financial officer, has been appointed acting ceo. He replaces Geert Nygaard.
Elan has named Hans Peter Hasler as chief operating officer.
The European Chemicals Agency (ECHA) management board has elected Nina Cromnier, the Swedish member, as its new chair for a two-year term. Cromnier has been the director general of the Swedish Chemicals Agency since 2010. Before that, she worked at the Swedish Ministry of Environment.
The Renewable Fuels Association (RFA) has elected Neill McKinstray, president of the ethanol division of The Andersons, as chairman. He succeeds Chuck Woodside.
Portugal-based international pharmaceutical company Hovione has made two appointments: Mike Ironside as general manager, TTC, in New Jersey, US and Conrad Winters as director, drug product development.
The board of pan-European specialty chemicals distributor Azelis has announced the appointment of Hans-Joachim Müller as the new ceo of Azelis Holding.
Bristol-Myers Squibb has named Frances Heller as senior vice president, business development. She will report to Lamberto Andreotti, ceo, and will be a member of the company’s senior management team.
BASF chair Kurt Bock, below, has been appointed president of the International Council of Chemical Associations (ICCA). He succeeds Andrew Liveris, chairman and ceo of Dow Chemical.
Bock has also elected president of the European Chemical Industry Council (Cefic). He replaces Giorgio Squinzi, chief executive of Mapei Group.
BASF has made two senior appointments: Jan- Peter Sander has been named senior vice president of BASF’s business unit Personal Care Europe. He will be responsible for all areas of the business, including manufacturing, supply chain, technology, marketing and sales. Scott Thomson will assume the role of senior vice president in charge of BASF’s Pharma Ingredients & Services business unit.
GW Pharmaceuticals has appointed Christopher Tovey to the newly created position of chief operating officer. Tovey was previously vice-president global marketing operations at UCB Pharmaceuticals.
Novasep, a provider of purification-based manufacturing solutions for life science molecules, has announced the appointment of Roger-Marc Nicoud, founder and ceo, as non-executive chairman of the board.
The UK BioIndustry Association (BIA) has appointed Harren Jhoti and Will West to its board. In addition, Allan Marchington, has been re-appointed to the board.
At GlaxoSmithKline (GSK), senior indepen- dent non-executive director Robert Wilson, right, has agreed to stand for re-election to the company’s board for one further year from May 2013. This is to provide continuity as GSK’s new board members settle into their roles. Larry Culp has decided to stand down from the board. Lynn Elsenhans has been
appointed a member of the corporate responsibility committee; Judy Lewent and former SCI Honorary President Stephanie Burns, above, have been appointed members of the remuneration committee; and Jing Ulrich has been appointed a member of the audit and risk committee – from which point Roy Anderson will step down.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64